Tofacitinib May Reduce Risk of Interstitial Lung Disease in RA Patients

(MedPage Today) -- Tofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the incidence of interstitial lung...
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news